In CML, the Abl kinase inhibitor imatinib induced apoptosis that was reversed when HO-1 was overexpressed, showing that HO-1 has cytoprotective effects in this type of cancer. This evidence concerns the gene HMOX1 and chronic myelogenous leukemia, BCR-ABL1 positive.